EPISODE · May 14, 2026 · 5 MIN
Immunic CEO on Q1 highlights, new appointments and upcoming milestones
from Proactive - Interviews for investors · host Proactive Investors
Immunic Inc (NASDAQ:IMUX, FRA:10VA) CEO Dr Daniel Vitt tells Proactive's Stephen Gunnion that the company is firmly on track to become a commercial-stage biotech, with Phase 3 readouts from its ENSURE-1 and ENSURE-2 relapsing multiple sclerosis trials expected by the end of 2026 and an NDA filing targeted for 2027. A $400 million oversubscribed financing — with $200 million already in hand — has given Immunic the firepower to see it through. Vitt says the level of investor support reflects confidence in the clinical data and the scale of the opportunity across both relapsing and progressive MS. New CMO Dr Michael Panzara brings deep neurology expertise to support the final stretch toward potential approval, while fresh board appointments, including seasoned biopharmaceutical executive Jon Congleton and Thor Nagel of BVF Partners, signal growing institutional commitment. On vidofludimus calcium itself, Vitt is direct: "The drug is the first activator of Nurr1, and with that has the potential to be a direct neuroprotective molecule" — something he describes as having "game-changing potential" for patients. For more videos like this, visit the Proactive YouTube channel, give this video a like, subscribe to the channel and enable notifications so you never miss future content. #Immunic #MultipleSclerosis #MSResearch #Biotech #Biotechnology #Healthcare #VidofludimusCalcium #Neurology #ClinicalTrials #Phase3 #Nurr1 #DrugDevelopment #MedTech #PharmaNews #Investing #HealthcareInnovation #ProgressiveMS #RelapsingMS #BiotechStocks #ProactiveInvestors
What this episode covers
Immunic Inc (NASDAQ:IMUX, FRA:10VA) CEO Dr Daniel Vitt tells Proactive's Stephen Gunnion that the company is firmly on track to become a commercial-stage biotech, with Phase 3 readouts from its ENSURE-1 and ENSURE-2 relapsing multiple sclerosis trials expected by the end of 2026 and an NDA filing targeted for 2027. A $400 million oversubscribed financing — with $200 million already in hand — has given Immunic the firepower to see it through. Vitt says the level of investor support reflects confidence in the clinical data and the scale of the opportunity across both relapsing and progressive MS. New CMO Dr Michael Panzara brings deep neurology expertise to support the final stretch toward potential approval, while fresh board appointments, including seasoned biopharmaceutical executive Jon Congleton and Thor Nagel of BVF Partners, signal growing institutional commitment. On vidofludimus calcium itself, Vitt is direct: "The drug is the first activator of Nurr1, and with that has the potential to be a direct neuroprotective molecule" — something he describes as having "game-changing potential" for patients. For more videos like this, visit the Proactive YouTube channel, give this video a like, subscribe to the channel and enable notifications so you never miss future content. #Immunic #MultipleSclerosis #MSResearch #Biotech #Biotechnology #Healthcare #VidofludimusCalcium #Neurology #ClinicalTrials #Phase3 #Nurr1 #DrugDevelopment #MedTech #PharmaNews #Investing #HealthcareInnovation #ProgressiveMS #RelapsingMS #BiotechStocks #ProactiveInvestors
NOW PLAYING
Immunic CEO on Q1 highlights, new appointments and upcoming milestones
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.